Anthony Zook Biography and Net Worth

CEO of NeoGenomics

Tony became CEO of NeoGenomics in April 2025. Prior to becoming CEO, he was a Board member for two years, serving as Chair of the Compensation committee and a member of the Audit and Technology committees. Tony has significant experience as a brand and marketing executive, with a focus on managing the interface between commercial and research and development aspects of an organization. Prior to serving as Chief Executive Officer of Innocoll Biotherapeutics, Tony was Executive Vice President, Commercial Operations of AstraZeneca (AZ), where he held global P&L responsibility for all of AZ’s brands and markets. Under Tony’s leadership, AZ commercialized 10 brands, each in excess of $1 billion in sales. Tony was responsible for MedImmune, AZ’s global biologics business. He also chaired the Commercial Investment Board, which identified and approved critical investments company-wide, including investments in plants, markets, and technology. Earlier in his career at AZ, Tony held various positions, including CEO of North America and VP of Sales, where he helped lead the integrations of Astra US, Astra Merck, and Zeneca. Prior to joining AZ, Tony spent 14 years with Berlex Laboratories in a variety of positions.

What is Anthony P. Zook's net worth?: The estimated net worth of Anthony P. Zook is at least $230.01 thousand as of May 6th, 2025. Mr. Zook owns 18,900 shares of NeoGenomics stock worth more than $230,013 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Zook may own. Learn More about Anthony P. Zook's net worth.
How do I contact Anthony P. Zook?: The corporate mailing address for Mr. Zook and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Anthony P. Zook's contact information.
Has Anthony P. Zook been buying or selling shares of NeoGenomics?: Anthony P. Zook has not been actively trading shares of NeoGenomics during the past quarter. Most recently, on Tuesday, May 6th, Anthony P. Zook bought 18,900 shares of NeoGenomics stock. The stock was acquired at an average cost of $7.88 per share, with a total value of $148,932.00. Following the completion of the transaction, the chief executive officer now directly owns 18,900 shares of the company's stock, valued at $148,932. Learn More on Anthony P. Zook's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Stephen Kanovsky (Director), Michael Kelly (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), Alicia Olivo (Executive Vice President, General Counsel & Business Development), David Perez (Director), Jeffrey Sherman (CFO), Robert Shovlin (Insider), Warren Stone (President and Chief Operating Officer), Lynn Tetrault (Director), and Anthony Zook (CEO). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, NeoGenomics insiders bought shares 7 times. They purchased a total of 70,600 shares worth more than $550,438.00. During the last year, insiders at the medical research company sold shares 1 times. They sold a total of 20,916 shares worth more than $250,992.00. The most recent insider tranaction occured on November, 25th when EVP Alicia C Olivo sold 20,916 shares worth more than $250,992.00. Insiders at NeoGenomics own 2.4% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/25/2025.

Anthony P. Zook Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/6/2025	Buy	18,900	$7.88	$148,932.00	18,900

Anthony P. Zook Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $12.17

$11.94

$12.26

50 Day Range

MA: $10.21

$7.72

$12.34

2 Week Range

Now: $12.17

$4.72

$19.11

Volume

1,233,955 shs

Average Volume

1,981,554 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6